Wave Life Sciences suvodirsen data with little read-through for efficacy, says SVB Leerink. Leerink analyst Mani Foroohar says that Wave Life Sciences’ first-in-human safety data from the Phase I trial of suvodirsen in exon 51 skipping-amenable Duchenne Muscular Dystrophy shows that it was generally sage and well-tolerated up to the 5mg/kg dose, and notes the company has selected the 3.0mg/kg and 4.5mg/kg doses to pivotal trials. While the stock is trading down and investors seem to see negative read-throughs for the potential efficacy of suvodirsen at 5mg/kg, given that drisapersen was dosed at 6mg/kg in clinical trials, the analyst believes that due to differences in chemistry between the compounds, comparison of doses between drugs is not appropriate proxy of potential efficacy. Foroohar maintains his 30% probability of success on the suvodirsen program and reiterates an Outperform rating on the shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.